Partnership for Safe Medicines Files a Citizen Petition Urging the FDA Not to Allow Compounding of Seven Peptides

A drug-safety group has asked the Food and Drug Administration to shut the door on compounded peptides. On October 23, 2026, the Partnership for Safe Medicines filed a citizen petition urging the FDA not to let pharmacies compound seven peptide bulk drug substances, including the popular recovery peptide BPC-157. The filing arrives as the FDA weighs a separate interim access policy that would ease peptide compounding, a policy that just finished White House review.

What the petition asks the FDA to do

The petition, filed under the FDA's citizen petition rule (21 CFR 10.30), asks the agency to refrain from allowing compounding of seven peptide bulk drug substances: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon. It asks the FDA to block that compounding through every available route: adding the peptides to the 503A Bulks List, placing them in Category 1 of the FDA's 503A interim policy, or exercising enforcement discretion. The petition further asks the FDA not to rely on its July 2026 advisory committee to satisfy the statutory step of convening and consulting an advisory panel before any such rulemaking.

Who filed it

The Partnership for Safe Medicines is a Washington-based coalition that campaigns against counterfeit and unapproved medicines. Its executive director, Shabbir Safdar, signed the petition. The group has opposed looser peptide rules before, submitting comments against the seven substances to the FDA's advisory committee in July 2026. In the petition, PSM says it purchased five peptide products from licensed pharmacies that it contends were compounded and shipped in violation of Section 503A, which it offers as evidence that oversight is already failing.

The core argument: the peptides fail the legal test

Under Section 503A of the Federal Food, Drug and Cosmetic Act, a pharmacy may compound from a bulk drug substance only if the substance has a federal quality monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List. The petition argues the seven peptides meet none of those conditions and cannot lawfully be added to the list. It leans on the FDA's own record: in briefing documents for the July meeting, the agency's career scientists recommended against adding all seven, citing poor chemical characterization, missing human safety and efficacy data, and immunogenicity risks. PSM argues that listing the peptides anyway would be arbitrary and capricious under the Administrative Procedure Act, and would reverse, without explanation, the FDA's September 2023 decision to flag more than a dozen peptides as presenting significant safety risks.

The conflict-of-interest claim against the July panel

A second line of attack targets the Pharmacy Compounding Advisory Committee that met on July 23 and 24, 2026. That panel voted to recommend six of the seven peptides for the 503A list, overriding FDA staff. The petition contends the panel was not lawfully constituted. It alleges that several members added shortly before the meeting had financial ties to clinics or companies that prescribe or sell peptides, citing reporting by STAT and the Washington Post, and that the FDA issued no conflict-of-interest waivers. On that basis PSM argues the panel ran afoul of the Federal Advisory Committee Act and federal ethics law, and that its vote should carry no weight. The petition notes that the representative of the U.S. Pharmacopeia, a standing member, voted against all seven peptides. The FDA has not ruled on these allegations.

How it fits the larger peptide fight

The petition is one move in a fast-moving dispute. HHS Secretary Robert F. Kennedy Jr. has pushed to give compounding pharmacies a path to supply peptides, arguing that patients are otherwise buying them from an unregulated gray market. The FDA sent a separate interim access policy for peptide compounding to the White House Office of Management and Budget on October 14, 2026. That review concluded by October 28: the action is no longer listed as pending, though the policy has not been issued or published and its terms are not public. PSM's petition asks the FDA to hold the line before any such policy or listing takes effect.

What a citizen petition can and cannot do

A citizen petition is a formal request, not a binding order. The FDA must docket it, take comment, and respond, and under its own rules it generally aims to answer within 180 days, though many petitions wait far longer, and the agency can grant, deny, or grant in part. Filing the petition does not by itself stop the FDA from issuing the interim policy or adding peptides to any list. Its practical weight comes from the administrative record it builds: a denial that fails to engage the petition's legal arguments can become grounds for a later court challenge.

What it means for telehealth and patients

Peptides reach most consumers through telehealth and wellness clinics, so the outcome of this fight will land on that channel. If the FDA eases access, those companies gain a clearer legal footing to offer certain peptides by prescription. If the agency sides with petitions like this one, the status quo holds and compounding these peptides stays legally exposed. For now, nothing in the petition changes the current rules: it is a request, and the FDA has not acted on it. Peptides such as BPC-157 remain unapproved, and the agency has repeatedly warned about contamination and other risks in products sold outside the approval system. This is general information, not medical or legal advice. Anyone weighing peptide treatment should consult a licensed clinician and rely on a verified pharmacy that can provide a certificate of analysis.

Limits and open questions

The petition reflects one group's position, and its central claims, that the July panel was conflicted and that the peptides cannot lawfully be listed, are arguments the FDA has not ruled on. The agency has not said how it will respond, or whether the conclusion of the interim policy's White House review means the policy will issue, be revised, or be withdrawn. The specific terms of that policy, including which peptides it would cover, remain unknown until the FDA publishes it.